One of the most effective cancer treatments is surgery. Unfortunately, some cancers are inoperable because of their location, because they have become too widely dispersed through metastasis to secondary sites, or because they are not solid tumors. In the absence of surgery, chemotherapy and radiation therapy are the remaining options, both of which can be rather nonselective and have severe side effects. Thus, the ability to personalize therapies on the basis of the tumor's oncogenic signaling profi le may enable clinicians to devise therapies that are maximally effective and minimally toxic.
Leukemia is a cancer of the white blood cells, with some forms common in children and some common in adults. In the 26 March issue, Hartzell et al. and Casado et al. report on signaling pathways altered in two forms of leukemia, T cell acute lymphoblastic leukemia/lymphoma (T-ALL) and acute myeloid leukemia (AML), respectively. Signaling mediated by the guanosine triphosphatase (GTPase) Ras, which activates the proliferative mitogen-activated protein kinase (MAPK) pathway, is frequently aberrant in T-ALL, but relatively few patients have mutations in the Ras-encoding gene, leading Hartzell et al. to investigate what other mutations could dysregulate this pathway. By screening more than 100 pediatric T-ALL patients, they identifi ed the Ras activator RasGRP1 as a potential contributor to this cancer. Increased RasGRP1 abundance enhanced Ras signaling and increased the proliferation of T-ALL cells, whereas reducing RasGRP1 abundance had the opposite effect.
Screening patients with this cancer for increased abundance of RasGRP1 may enable customized treatment. Casado et al. focused their attention on AML cells. They combined phosphoproteomic analysis with a computational approach to boost the signal-to-noise ratio in their investigation of kinase activation patterns and the effects of select kinase inhibitors on kinase networks. Because this approach accurately predicted the relative sensitivities of patient-derived AML cells to inhibitors, such profi ling of kinase networks could be applied to stratify cancers based on their predicted responses to kinase inhibition.
Kinase inhibitors, especially tyrosine kinase inhibitors, are clinically important, but many patients develop resistance to these drugs and relapse. Thus, combination therapies are needed to prevent or overcome such resistance. In the 26 March issue, Bean et al. (see the Perspective by Roulston et al.) explore the relationship between signaling of receptor tyrosine kinases and cell death (apoptosis) pathways in cancer cells "addicted" to specifi c receptor tyrosine kinases for survival. Their analysis of non-small cell lung cancers and a specifi c type of breast cancer suggests that combining drugs that inhibit antiapoptotic proteins with oncogenic kinase inhibitors may overcome drug resistance in cancer patients.
Clearly, kinase inhibitors are not the only options for rational, personalized therapeutic intervention. Protein interactions may also be important targets. Identifying different subpopulations of cancer cells may yield signatures of both invasive cells and cells that might be resistant or sensitive to specifi c therapies. Wood et al. developed a screening and imaging analysis method to perform high-throughput screening and applied their method to identify proteins that infl uenced the sensitivity of melanoma cells to various clinically used antineoplastic agents. Understanding cancer heterogeneity at the genomic level is becoming possible with large-scale tumor sequencing efforts. As Yaffe highlights in a Perspective in the 2 April issue, the challenge now is to integrate this information with other systems-level studies, such as gene expression data, proteomic and posttranslational modifi cation data, and analysis of the dynamics of signaling and metabolic networks. The Protocol by Gao et al. in the 2 April issue provides a step-by-step guide to cBioPortal, an online resource for interactively exploring genetic alterations across tumor samples, as well as changes in messenger RNA (mRNA) and microRNA expression, DNA methylation, protein abundance, and phosphoprotein abundance. These tools and the research highlighted here suggest that understanding the molecular mechanisms underlying cancer is an attainable goal and present hope for effectively combating this dreaded disease. 
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